KR20230173129A - 화합물 smtp-7을 포함하는 약제학적 조성물 - Google Patents

화합물 smtp-7을 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR20230173129A
KR20230173129A KR1020237038571A KR20237038571A KR20230173129A KR 20230173129 A KR20230173129 A KR 20230173129A KR 1020237038571 A KR1020237038571 A KR 1020237038571A KR 20237038571 A KR20237038571 A KR 20237038571A KR 20230173129 A KR20230173129 A KR 20230173129A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
additive
smtp
composition according
polyoxyethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237038571A
Other languages
English (en)
Korean (ko)
Inventor
나오코 니시무라
케이코 하세가와
케이지 하스미
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20230173129A publication Critical patent/KR20230173129A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
KR1020237038571A 2021-04-20 2022-04-20 화합물 smtp-7을 포함하는 약제학적 조성물 Pending KR20230173129A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021070892 2021-04-20
JPJP-P-2021-070892 2021-04-20
PCT/US2022/025462 WO2022226013A1 (en) 2021-04-20 2022-04-20 Pharmaceutical composition comprising the compound smtp-7

Publications (1)

Publication Number Publication Date
KR20230173129A true KR20230173129A (ko) 2023-12-26

Family

ID=81648879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237038571A Pending KR20230173129A (ko) 2021-04-20 2022-04-20 화합물 smtp-7을 포함하는 약제학적 조성물

Country Status (9)

Country Link
US (1) US20240238252A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326258A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525239A (cg-RX-API-DMAC7.html)
KR (1) KR20230173129A (cg-RX-API-DMAC7.html)
CN (1) CN117279634A (cg-RX-API-DMAC7.html)
AU (1) AU2022262593A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021803A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214630A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022226013A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238248A1 (en) * 2021-05-10 2024-07-18 Ji Xing Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
JPWO2007040082A1 (ja) 2005-10-06 2009-04-16 国立大学法人東京農工大学 腎炎治療又は予防用医薬組成物及びその製造方法
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
JP2008201688A (ja) * 2007-02-16 2008-09-04 Tms Co Ltd 皮膚老化防止剤、化粧料及び皮膚外用剤
JP5605659B2 (ja) * 2009-07-06 2014-10-15 国立大学法人東京農工大学 細胞保護剤
WO2011125930A1 (ja) 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
JP7381035B2 (ja) * 2018-11-02 2023-11-15 学校法人昭和大学 Smtp一群又はsmtp-7の製造中間体及びその化学的製造方法
US20240238248A1 (en) * 2021-05-10 2024-07-18 Ji Xing Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction

Also Published As

Publication number Publication date
WO2022226013A1 (en) 2022-10-27
JP2024525239A (ja) 2024-07-11
CA3214630A1 (en) 2022-10-27
CN117279634A (zh) 2023-12-22
AU2022262593A1 (en) 2023-11-02
BR112023021803A2 (pt) 2024-01-23
US20240238252A1 (en) 2024-07-18
EP4326258A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7042531B2 (ja) デオキシコール酸を含む医薬組成物
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
JP5522877B2 (ja) モキシフロキサシン/塩化ナトリウム製剤
JP2010523696A (ja) 脳腫瘍を治療する方法
KR20200018485A (ko) 우울 장애들의 치료
CN104918619A (zh) 稳定的肠胃外dnj组合物
KR102656841B1 (ko) 레파뮬린의 주사가능한 약제학적 제형
US20240238252A1 (en) Pharmaceutical composition comprising the compound smtp-7
EP4223313A1 (en) Pharmaceutical composition comprising acid-base neutralization combination and application thereof
CN120265283A (zh) (-)-表没食子儿茶素没食子酸酯类化合物的应用
EP4495122A1 (en) Artemisinin derivatives, preparation method therefor, and uses thereof
JP7857158B2 (ja) 透析患者に適用される注射用医薬組成物
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
EP1941880B1 (en) Lotion preparation containing pyridonecarboxylic acid derivative
US7262317B2 (en) Freeze-dried preparation of n[o-(p-pivaloyloxybenzenasulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing same
WO2004098614A1 (ja) メチルコバラミン含有凍結乾燥製剤及びその製造方法
HK40105250A (en) Pharmaceutical composition comprising the compound smtp-7
US20240024299A1 (en) Use of drugs that stiffen mature gametocytes for blocking transmission of plasmodium parasites
KR20120089444A (ko) 정맥내 이부프로펜에 의한 위독한 환자의 치료방법
KR20080096829A (ko) 정맥내 항바이러스 치료
US20240415815A1 (en) Ionic-liquid-based formulations for the prevention or treatment of neurological diseases
WO2026013454A1 (en) Multi-dose pen of tirzepatide
EP4415720A1 (en) Novel parenteral composition comprising linagliptin or its salts
WO2020188457A1 (en) Solutions for oral dosage
HK1179530B (en) Treatment of loss of sense of touch with saxitoxin derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)